COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock
70.41 USD
+1.77 (+2.58%)
CNS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 235 industry peers in the Capital Markets industry. While CNS has a great profitability rating, there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CNS was profitable.
- CNS had a negative operating cash flow in the past year.
- CNS had positive earnings in each of the past 5 years.
- Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 20.48%, CNS belongs to the best of the industry, outperforming 97.87% of the companies in the same industry.
- CNS has a better Return On Equity (29.83%) than 95.74% of its industry peers.
- With an excellent Return On Invested Capital value of 24.24%, CNS belongs to the best of the industry, outperforming 98.30% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.17%.
- The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
- CNS has a better Profit Margin (29.73%) than 73.62% of its industry peers.
- In the last couple of years the Profit Margin of CNS has declined.
- The Operating Margin of CNS (33.83%) is better than 65.53% of its industry peers.
- In the last couple of years the Operating Margin of CNS has declined.
- The Gross Margin of CNS (88.60%) is better than 93.19% of its industry peers.
- In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
- CNS has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, CNS has more shares outstanding
- CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CNS has an Altman-Z score of 9.56. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 9.56, CNS belongs to the top of the industry, outperforming 94.89% of the companies in the same industry.
- CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.56 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
- CNS has a Current ratio of 0.79. This is in the lower half of the industry: CNS underperforms 62.98% of its industry peers.
- CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
- CNS has a worse Quick ratio (0.79) than 62.55% of its industry peers.
- The current and quick ratio evaluation for CNS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 8.87% over the past year.
- Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
- CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.13%.
- CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
- Based on estimates for the next years, CNS will show a small growth in Earnings Per Share. The EPS will grow by 7.68% on average per year.
- CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.21% yearly.
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 22.93, CNS is valued on the expensive side.
- CNS's Price/Earnings is on the same level as the industry average.
- The average S&P500 Price/Earnings ratio is at 27.33. CNS is around the same levels.
- The Price/Forward Earnings ratio is 20.46, which indicates a rather expensive current valuation of CNS.
- The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
- CNS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.93 | ||
| Fwd PE | 20.46 |
4.2 Price Multiples
- 78.30% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.16 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
- CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.03
PEG (5Y)9.18
EPS Next 2Y8.37%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
- CNS has a Yearly Dividend Yield of 3.69%.
- CNS's Dividend Yield is comparable with the industry average which is at 6.19.
- CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.69% |
5.2 History
- The dividend of CNS decreases each year by -7.12%.
- CNS has paid a dividend for at least 10 years, which is a reliable track record.
- CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
- CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
NYSE:CNS (1/15/2026, 11:29:42 AM)
70.41
+1.77 (+2.58%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-16 2025-10-16/amc
Earnings (Next)01-28 2026-01-28/amc
Inst Owners58.73%
Inst Owner Change0.04%
Ins Owners22.81%
Ins Owner Change3.32%
Market Cap3.59B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (11.55%)
Short Float %6.31%
Short Ratio4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.69% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.35%
PT rev (3m)-1.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.93 | ||
| Fwd PE | 20.46 | ||
| P/S | 6.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.53 | ||
| P/tB | 6.77 | ||
| EV/EBITDA | 17.16 |
EPS(TTM)3.07
EY4.36%
EPS(NY)3.44
Fwd EY4.89%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)5.03
PEG (5Y)9.18
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 9.56 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.2%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
What is the valuation status for CNS stock?
ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
Can you provide the financial health for CNS stock?
The financial health rating of COHEN & STEERS INC (CNS) is 6 / 10.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.